Composition with reduced immunogenicity
US11084871B2 · kind B2 · utility
1Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 17, 2014 |
| Grant date | Aug 10, 2021 |
| Priority date | — |
| Expiry date | Apr 17, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/40
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a composition comprising polyclonal antibodies directed against human cells, wherein the said polyclonal antibodies are devoid of a first antigenic determinant selected in a group comprising (i) N-glycol-neuraminic acid (Neu5Gc) and (ii) α-1,3-galactose and its use as a medicament.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.